SEC Form 8-K Summary
Business Context and Reporting Period
Deep Medicine Acquisition Corp., a Delaware special purpose acquisition company, filed this Form 8-K on October 24, 2022, under Item 7.01 (Regulation FD Disclosure). The filing concerns an appointment effective October 15, 2022. The provided filing text does not identify Trugolf Holdings, Inc. as the registrant; the registrant is Deep Medicine Acquisition Corp.
Material Event
- John Chiang was appointed as a director of the company, effective October 15, 2022.
- The company issued a related press release on October 24, 2022, furnished as Exhibit 99.1.
Financial Metrics and Capitalization
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating or financial metrics.
Outlook, Risks, and Unusual Items
No management outlook, financial guidance, material risk update, contingency, or unusual financial item is disclosed in the provided text. Information under Item 7.01 and Exhibit 99.1 is furnished and is not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly provided by reference.
Investor Verification Items
- Verify the registrant and transaction context, because the filing identifies Deep Medicine Acquisition Corp., not Trugolf Holdings, Inc.
- Review Exhibit 99.1 for additional details regarding John Chiang’s appointment and background.
- Confirm the effective appointment date of October 15, 2022, versus the press release date of October 24, 2022.
- Assess whether subsequent filings describe any broader board, governance, or business combination implications.